Yao Ren Jie, Simonato Matheus, Dvir Danny
Department of Cardiology, St Paul's Hospital, Vancouver, Canada.
Interv Cardiol. 2017 May;12(1):40-43. doi: 10.15420/icr.2016:25:2.
Bioprosthetic surgical valves are increasingly implanted during cardiac surgery, instead of mechanical valves. These tissue valves are associated with limited durability and as a result transcatheter valve-in-valve procedures are performed to treat failed bioprostheses. A relatively common adverse event of aortic valve-in-valve procedures is residual stenosis. Larger surgical valve size, supra-annular transcatheter heart valve type, as well as higher transcatheter heart valve implantation depth, have all been shown to reduce the incidence of elevated post-procedural gradients. With greater understanding of technical considerations and surgical planning, valve-in-valve procedures could be more effective and eventually may become the standard of care for our increasingly ageing and comorbid population with failed surgical bioprostheses.
在心脏手术中,生物人工心脏瓣膜越来越多地被植入,而非机械瓣膜。这些组织瓣膜的耐久性有限,因此会进行经导管瓣中瓣手术来治疗失效的生物瓣膜。主动脉瓣中瓣手术相对常见的不良事件是残余狭窄。已证实,更大尺寸的外科手术瓣膜、瓣环上经导管心脏瓣膜类型以及更深的经导管心脏瓣膜植入深度,均可降低术后梯度升高的发生率。随着对技术考量和手术规划的深入理解,瓣中瓣手术可能会更有效,最终或许会成为我们日益老龄化且合并症增多的生物瓣膜失效患者的标准治疗方法。